Eli Lilly Faces Mounting Competition in Weight-Loss Drug Arena

While Eli Lilly continues to post impressive prescription figures for its blockbuster weight-loss medications, a growing sense of unease is emerging among its investors. The lucrative market for anti-obesity injections is becoming increasingly contested, as evidenced by recent advancements from rivals Novo Nordisk and Viking Therapeutics.

Robust Prescription Data Meets Market Pressures

The company’s internal metrics remain strong. Weekly prescription data as of March 20, 2026, underscores sustained demand:
* Mounjaro: 729,600 total prescriptions, including 359,900 new patient starts.
* Zepbound: 608,600 total prescriptions, with 326,400 of those being new prescriptions.

Despite these solid fundamentals, Eli Lilly’s shares declined by 2.30 percent on Friday, closing at €761.70. This movement brought the stock to within approximately one percent of its closely watched 200-day moving average. Investor caution appears driven by competitive developments and a recent rating downgrade from HSBC.

The competitive landscape is heating up. Novo Nordisk’s new oral version of Wegovy is gaining significant traction, recording nearly 95,000 prescriptions in its eleventh week on the market. Simultaneously, Viking Therapeutics announced the completion of patient recruitment for a pivotal Phase 3 trial of its own dual-mechanism drug candidate. These updates have temporarily overshadowed Lilly’s own positive operational data.

Should investors sell immediately? Or is it worth buying Eli Lilly?

Analyst Confidence Endures

Major investment banks are not swayed by the short-term market weakness. Both Morgan Stanley and Jefferies reaffirmed their Buy ratings on Friday, with price targets exceeding $1,300. Analysts point to the persistently high demand for the company’s GLP-1 and GIP agonist drugs as their primary rationale for maintaining a bullish outlook.

Pipeline Progress Strengthens Long-Term Position

Beyond the immediate rivalry in obesity care, Eli Lilly is advancing its clinical research pipeline in other areas. At a recent dermatology congress, the company presented promising long-term data for EBGLYSS, which showed 94 percent of patients achieving significant skin clearance after four years.

More critical to its long-term growth narrative are the recent Phase 3 results for the triple-agonist Retatrutide. Demonstrating an average weight reduction of 16.8 percent over 40 weeks, Eli Lilly is concretely positioning itself for the next generation of metabolic therapies. This progress serves to fortify its market standing against emerging competitors.